Mayne Pharma growth strategy in Women’s health - ASX SMIDcaps Conference

Core Insights - Mayne Pharma Group Limited is focusing on women's health and dermatology markets in the United States, with a strategy aimed at expanding access to its products and enhancing patient outcomes [1][3] Business Units - The company operates across three business units, with two generating all revenue from the US, specifically targeting women's health and dermatology, while the third unit covers Australia and other global markets [2] Women's Health Portfolio - Mayne Pharma's women's health portfolio includes four reproductive health products that address contraception and menopause treatment, which are described as "best in class" [2][3] - Innovations in this portfolio include plant-derived estrogen therapies and combination drug-device solutions aimed at improving patient access and outcomes [3] Dermatology Products - The company offers 31 dermatology products targeting conditions such as psoriasis and acne, and has maintained profitability despite challenges in insurance reimbursement [3] Financial Performance - In the first half of the year, Mayne Pharma reported $212 million in revenue and generated $16.9 million in operating cash flow, which were characterized as "very resilient" results in a challenging environment [3] Future Focus - Looking ahead, the company aims to expand access strategies, strengthen its salesforce, and capitalize on growth opportunities in the US hormone replacement therapy market [4] - Mayne Pharma has strong fundamentals, including patent protection and growing market share, with significant potential to capture more market share [4]